[The effect of recombinant alfa-2 interferon (reaferon) on the functional activity of natural killers in acute viral hepatitis B]. 1995

I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 1986, Terapevticheskii arkhiv,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 1998, Likars'ka sprava,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 1994, Vojnosanitetski pregled,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
July 1989, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 2000, Vojnosanitetski pregled,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 1988, Terapevticheskii arkhiv,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
May 1990, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
March 1991, Klinicheskaia meditsina,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
July 1992, Orvosi hetilap,
I A Petrovskaia, and L Ia Kushko, and S V Fedorchenko, and A D Vovk, and N K Listopad, and S N Antoniak, and G N Drannik
January 1992, Pediatriia,
Copied contents to your clipboard!